STOCK TITAN

Plus Therapeutics (PSTV) CFO acquires 67,452 shares through RSU vesting

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

PLUS THERAPEUTICS Chief Financial Officer Andrew John Hugh MacIntyre Sims acquired shares through RSU vesting. On April 1, 2026, he exercised Restricted Stock Units to receive a total of 67,452 shares of Common Stock in two transactions of 38,323 and 29,129 shares at an exercise price of $0.00 per share.

Following these transactions, his direct holdings of Common Stock increased to 173,913 shares. Footnotes state that each Restricted Stock Unit represents a contingent right to receive one share of Common Stock and that the RSU grants vest in twelve substantially equal quarterly installments beginning on specified dates.

Positive

  • None.

Negative

  • None.
Insider Sims Andrew John Hugh MacIntyre
Role Chief Financial Officer
Type Security Shares Price Value
Exercise Restricted Stock Units 38,323 $0.00 --
Exercise Restricted Stock Units 29,129 $0.00 --
Exercise Common Stock 38,323 $0.00 --
Exercise Common Stock 29,129 $0.00 --
Holdings After Transaction: Restricted Stock Units — 694,451 shares (Direct); Common Stock — 144,784 shares (Direct)
Footnotes (1)
  1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock. Represents the vesting of an RSU grant which occurs in twelve substantially equal quarterly installments beginning on October 1, 2025. Represents the vesting of an RSU grant which occurs in twelve substantially equal quarterly installments beginning on April 1, 2026.
RSU shares exercised (block 1) 38,323 shares Restricted Stock Units exercised into Common Stock on April 1, 2026
RSU shares exercised (block 2) 29,129 shares Restricted Stock Units exercised into Common Stock on April 1, 2026
Total RSU shares exercised 67,452 shares Aggregate RSU-derived Common Stock acquired on April 1, 2026
Exercise price per share $0.00 per share Price for Common Stock received upon RSU exercises
Common Stock held after transaction 173,913 shares Direct Common Stock ownership following April 1, 2026 transactions
RSU holding after first derivative entry 694,451 units Total RSUs reported following the 38,323-unit exercise entry
RSU holding after second derivative entry 665,322 units Total RSUs reported following the 29,129-unit exercise entry
Restricted Stock Units financial
"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right financial
"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock."
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
quarterly installments financial
"Represents the vesting of an RSU grant which occurs in twelve substantially equal quarterly installments"
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sims Andrew John Hugh MacIntyre

(Last)(First)(Middle)
C/O PLUS THERAPEUTICS INC.
6420 LEVIT GREEN BOULEVARD, SUITE 310

(Street)
HOUSTON TEXAS 77021

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
PLUS THERAPEUTICS, INC. [ PSTV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/01/2026M38,323(2)A$0(1)144,784D
Common Stock04/01/2026M29,129(3)A$0(1)173,913D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units$004/01/2026M38,323 (2) (2)Common Stock38,323$0694,451D
Restricted Stock Units$004/01/2026M29,129 (3) (3)Common Stock29,129$0665,322D
Explanation of Responses:
1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock.
2. Represents the vesting of an RSU grant which occurs in twelve substantially equal quarterly installments beginning on October 1, 2025.
3. Represents the vesting of an RSU grant which occurs in twelve substantially equal quarterly installments beginning on April 1, 2026.
/s/ Andrew Sims04/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did PSTV’s CFO do in this Form 4 filing?

The CFO of PLUS THERAPEUTICS, Inc. exercised Restricted Stock Units on April 1, 2026 to acquire 67,452 shares of Common Stock. These transactions reflect equity compensation vesting rather than open-market purchases or sales.

How many PLUS THERAPEUTICS (PSTV) shares did the CFO acquire?

The CFO acquired 67,452 shares of Common Stock through RSU exercises, in two blocks of 38,323 and 29,129 shares. All were issued at an exercise price of $0.00 per share as part of vested equity awards.

What are Restricted Stock Units in the PSTV Form 4 filing?

In this filing, each Restricted Stock Unit (RSU) is described as a contingent right to receive one share of PLUS THERAPEUTICS Common Stock. When RSUs vest, they convert into actual shares delivered to the executive.

How many PLUS THERAPEUTICS shares does the CFO hold after these RSU exercises?

After the April 1, 2026 transactions, the CFO directly holds 173,913 shares of Common Stock. This total reflects his updated ownership position reported immediately following the RSU-related acquisitions.

How do the PSTV RSU grants vest for the CFO?

Footnotes state the RSU grants vest in twelve substantially equal quarterly installments, beginning on specific dates such as October 1, 2025 and April 1, 2026. As installments vest, corresponding RSUs convert into Common Stock.